Lv11
40 积分 2025-08-14 加入
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
2小时前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
7小时前
已完结
Exploiting the folate receptor α in oncology
4天前
已完结
皖公网安备34019202002308
